Antidepressant treatment history as a predictor of response to scopolamine: clinical implications-Reference-Cited by-同舟云学术

Antidepressant treatment history as a predictor of response to scopolamine: clinical implications

Published:2014-06 Issue: Volume:162 Page:39-42
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Ellis Jessica S.,Zarate Carlos A.,Luckenbaugh David A.,Furey Maura L.

Funder

NIH NIMH-DIRP Z01-MH002813

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference16 articles.

1. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, IV, Text Revision. American Psychiatric Association: Washington DC.

2. Replication of scopolamine׳s antidepressant efficacy: a randomized, placebo-controlled clinical trial;Drevets;Biol. Psychiatry.,2010

3. Definition and epidemiology of treatment-resistant depression;Fava;Psychiatr. Clin. North Am.,1996

4. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial;Furey;Arch. Gen. Psychiatry.,2006

5. Scopolamine produces larger antidepressant and antianxiety effects in women than in men;Furey;Neuropsychopharmacology,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depression and the Glutamate/GABA-Glutamine Cycle;Current Neuropharmacology;2024-08-15

2. The Potential of Scopolamine as an Antidepressant in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials;Biomedicines;2023-09-26

3. Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis;Neuropsychiatric Disease and Treatment;2023-05

4. Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review;CNS Drugs;2022-10-21

5. Rapid antidepressant-like effects of muscarinic receptor antagonists require BDNF-dependent signaling in the ventrolateral periaqueductal gray;Psychopharmacology;2022-10-12